

May 2011

# H02-A5

Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard—Fifth Edition

This document provides a description of the principle, materials, and procedure for a standardized erythrocyte sedimentation rate (ESR) method; a selected routine method, as well as a procedure to evaluate routine methods; and an outline of quality control programs for the ESR test.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

## **Clinical and Laboratory Standards Institute**

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

#### **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

#### **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

#### **Appeals Process**

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

#### Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA 19087 USA P: 610.688.0100 F: 610.688.0700 www.clsi.org standard@clsi.org

	H02-A5
ISBN 1-56238-753-7 (Print)	Vol. 31 No. 11
ISBN 1-56238-754-5 (Electronic)	Replaces H02-A4
ISSN 0273-3099	Vol. 20 No. 27
Procedures for the Erythrocyte Sedimentation Rate Test; Approved	

### Standard—Fifth Edition

Volume 31 Number 11

Josep M. Jou, MD, PhD Francesco Cocola Bruce H. Davis, MD Chiara Derioni John Dorman, MT(ASCP) John A. Koepke, MD S. Mitchell Lewis Renzo Montanari Monisha Parikh Mario Plebani, MD Susan S. Smith

#### Abstract

Clinical and Laboratory Standards Institute document H02-A5—*Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard*—*Fifth Edition* is a revision of the fourth edition approved standard (H02-A4) published in December 2000. The document outlines the necessary details for the performance of a standardized (Westergren) method on diluted (1:4) blood specimens for the determination of the erythrocyte sedimentation rate (ESR). Quality assurance and evaluation of other methods to measure the ESR are also described, including procedures for the preparation of a fresh blood reference material for use in the laboratory or manufacturing of ESR devices. This standard provides guidance for the validation, verification, quality assurance, and quality control of ESR measurement devices or related controls. The intended audience includes manufacturers of such devices, end-user clinical laboratories, accrediting organizations, and regulatory bodies.

Clinical and Laboratory Standards Institute (CLSI). Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard—Fifth Edition. CLSI document H02-A5 (ISBN 1-56238-753-7 [Print]; ISBN 1-56238-754-5 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2011.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



Number 11

H02-A5

Copyright <sup>©</sup>2011 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

#### **Suggested Citation**

CLSI. Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard—Fifth Edition. CLSI document H02-A5. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

**Proposed Standard** August 1971

**Tentative Standard** March 1972

Approved Standard October 1974

**Revised Tentative Standard** April 1975

**Revised Approved Standard** August 1977 **Tentative Standard—Second Edition** December 1982

Approved Standard—Second Edition August 1988

**Approved Standard—Third Edition** August 1993

**Approved Standard—Fourth Edition** December 2000

**Approved Standard—Fifth Edition** May 2011

ISBN 1-56238-753-7 (Print) ISBN 1-56238-754-5 (Electronic) ISSN 0273-3099

Volume 31

#### **Committee Membership**

#### **Consensus Committee on Hematology**

Dorothy M. Adcock, MD Chairholder Esoterix Coagulation Englewood, Colorado, USA

Stephen Kitchen, FIBMS, PhD Vice-Chairholder Royal Hallamshire Hospital Sheffield, United Kingdom

Maria J. Arroz, MD Hospital s. Francisco Xavier Servico de Patologia Clinica Lisbon, Portugal

#### Acknowledgment

Josephine M. Bautista, MS, MT(ASCP) FDA Center for Devices and Radiological Health Rockville, Maryland, USA

Douglas J. Christie, PhD, FAHA Siemens Healthcare Diagnostics Newark, Delaware, USA

Emmanuel Favaloro, PhD ICPMR, Westmead Hospital New South Wales, Australia Ian Giles, MD Sysmex America, Inc. Mundelein, Illinois, USA

Hans Hoffmann, PhD Abbott GmbH Wiesbaden, Germany

Powers Peterson, MD Quest Diagnostics Nichols Institute Valencia, California, USA

CLSI and the Consensus Committee on Hematology gratefully acknowledge the following individuals for their help in preparing the approved-level, fifth edition of this standard:

Josep M. Jou, MD, PhD Servei Hemoterapia i Hemostasia Hospital Clinic University of Barcelona Barcelona, Spain

Francesco Cocola Diesse Diagnostica Senese SPA Monteriggioni, Siena, Italy

Bruce H. Davis, MD Trillium Diagnostics, LLC Bangor, Maine, USA Chiara Derioni Alifax spa Polverara, Italy

John Dorman, MT(ASCP) Streck Laboratories, Inc Omaha, Nebraska, USA

John A. Koepke, MD Durham, North Carolina, USA

S. Mitchell Lewis Hammersmith Hospital London, United Kingdom Renzo Montanari Vital Diagnostics Srl Forli, Italy

Monisha Parikh BD Franklin Lakes, New Jersey, USA

Mario Plebani, MD University of Padova Padova, Italy

Susan S. Smith Sarstedt, Inc. Newton, North Carolina, USA

#### Staff

Clinical and Laboratory Standards Institute Wayne, Pennsylvania, USA

Lois M. Schmidt, DA Vice President, Standards Development

Jennifer K. Adams, MT(ASCP), MSHA Staff Liaison

Patrice Polgar Project Manager

Melissa A. Lewis, ELS Editorial Manager

Megan P. Larrisey, MA Assistant Editor

#### H02-A5

Number 11

H02-A5

Volume 31

## Contents

Abstra	ct		i
Comm	ittee Me	mbership	iii
Forewo	ord		vii
1	Scope.		1
2	Standard Precautions		
3	Terminology		
	3.1 3.2 3.3	A Note on Terminology Definitions Abbreviations and Acronyms	1
4	Precautions and Significant Variables in Performance of the Erythrocyte Sedimenta Rate		4
	4.1	Specimen Collection Variables	4
	4.2	Time and Temperature of Specimen Storage	
	4.3 4.4	Equipment Variables Methodological Variables	
5	Princip	Je	
6	· ·	es	
	6.1	Pipette	8
	6.2	Pipette Rack	
7	The Er	ythrocyte Sedimentation Rate Test: Standardized Procedure	8
	7.1	Blood Collection	
	7.2 7.3	Time of Test Specimen Preparation	
	7.3	Blood Cell Suspension	
	7.5	Handling of the Pipette	
	7.6	Reading of the Test	
	7.7	Reporting of the Test Results	
	7.8	Comparative Values for Routine Erythrocyte Sedimentation Rate Methods	
8	The Er	ythrocyte Sedimentation Rate Test: Selected Routine Method	
	8.1	Blood Specimen	
	8.2	Specimen Preparation	
	8.3 8.4	Handling of the Pipette Reading the Test Results	
	8.5	Reporting Test Results	
	8.6	Reference Values	
9	Quality	Assurance	12
	9.1	Use of Control Blood Specimens for Method Validation	12
	9.2	Troubleshooting Erythrocyte Sedimentation Rate Quality Control Problems	
	9.3	Proficiency Testing	13
10	Techni	cal Innovations for Erythrocyte Sedimentation Rate Testing	13
Refere	nces		15

H02-A5

Number 11

## **Contents (Continued)**

Appendix. Protocol for Evaluation of Routine/Working Erythrocyte Sedimentation Rate Methods	
Against the Standardized Method	18
The Quality Management System Approach	22
Related CLSI Reference Materials	23

Volume 31

H02-A5

#### Foreword

The erythrocyte sedimentation rate (ESR) test, first described about 70 years ago,<sup>1-3</sup> is one of the most widely performed laboratory tests. The Westergren method<sup>2,3</sup> to measure the ESR has remained essentially unchanged since its inception and was recommended as the method of choice by the International Council (previously Committee) for Standardization in Haematology (ICSH) in 1973<sup>4</sup> and 1977.<sup>5</sup> Subsequently, in 1993, ICSH recommended the use of undiluted blood and adjustment of the hematocrit to 0.35 L/L or lower.<sup>6</sup> Although over the years, other methods to measure the ESR were introduced for routine use (eg, the Wintrobe method<sup>7</sup> and the zeta sedimentation ratio [ZSR] determination),<sup>8</sup> the Westergren method remains the benchmark against which other methods can be, and are, evaluated.

This fifth edition reflects a unifying approach to optimal use of all the current ESR methods. Of particular note is that upon review of the current literature and available expert opinion this edition now recommends a standardized method using diluted blood, thus revising the standardization method for the ESR.

Over the last few years, a number of technical innovations and semiautomated instruments were introduced to eliminate or decrease the risk of exposure of laboratory workers to potentially infectious material, eg, blood. The newer procedures are considered less hazardous, primarily because they are either self-contained or use disposable materials, or both. There is a need to examine these innovations, both for comparability of results to previously employed methods and to ensure, on an ongoing basis, the quality assurance of the results. This document provides standardized methods to address these needs.

Erythrocyte sedimentation is a nonspecific reaction; it is a measure of the presence and severity of pathological processes. In general, the ESR is increased in acute, general infections and in localized, acute, inflammatory conditions. Variations in the ESR depend on the nature and severity of the disease process. The usefulness of ESR is in evaluating patients with unexplained symptoms when inflammation and infectious disease are suspected and a specific diagnosis is not available effectively using other tests. No evidence supports the use of ESR in asymptomatic individuals and the test should not be included in routine investigations aimed to monitor the health status. ESR provides useful information when used as a diagnostic criterion for temporal arteritis, polymyalgia rheumatica, monitoring the activity of giant cell arteritis, and inflammatory arthropathies, as well as following the course of patients with rheumatoid arthritis.<sup>9-17</sup>

On occasion, the ESR may increase where other clinical and laboratory evaluations yield negative results. This should nonetheless be regarded as a sign of disease until such time as the physician is fully satisfied that the patient is perfectly well. However, normal values for the ESR were found in patients with a neoplasm of the liver<sup>18</sup> or with other serious conditions.<sup>19</sup> The ESR was used to differentiate organic disease from functional disorders, or as a guide to the progress of diseases such as rheumatic carditis, rheumatoid arthritis, and certain malignancies, including Hodgkin's disease.

ESR procedures cannot be calibrated. The procedures used to determine the ESR are susceptible to a variety of errors. An inadequately performed ESR that produces an incorrect result may not be detected unless some reference material is available in the laboratory where the ESR procedure is performed. Because the phenomenon of erythrocyte sedimentation is confined to fresh blood and is transient, presently, the only feasible way of providing a control material is for the manufacturer or test developer to specify a method for the production of such material in the laboratory where it will be used. Because of the nature of the human erythrocyte sedimentation reaction, reference or control materials of the usual type are not available for the ESR test.

Number 11

H02-A5

#### **Foreword (Continued)**

This document describes a standardized procedure for the ESR test, as well as a selected procedure. This standardized method is based on the original methodology of Fåhraeus<sup>1</sup> and Westergren,<sup>3</sup> which used diluted blood in open-ended, Westergren-type glass pipettes of 300-mm length, mounted vertically in a rack or stand. The standardized procedure was verified in studies based on an ICSH procedure.<sup>6</sup> The procedures described in this document are an attempt to measure the ESR in a fashion that is not misleadingly influenced by variations in relative erythrocyte volume. The procedures also permit the preparation of a standardized material for test validation within the laboratory. Such a material, of necessity fresh whole blood, can then be used in the laboratory to ensure the quality of the method(s) routinely in use to determine the ESR.

The document outlines the necessary details for the performance of a standardized (Westergren) method on diluted (1:4) blood specimens for the determination of the ESR. Quality assurance and evaluation of other methods to measure the ESR are also described, including procedures for the preparation of a fresh blood reference material for use in the laboratory. This standard will enable the user of commercial, disposable ESR equipment to ensure that both the test equipment and test procedures are performing adequately.

#### **Key Words**

Erythrocyte sedimentation, erythrocyte sedimentation rate (ESR) test, quality control, selected procedure, standardized procedure, Westergren pipette

Volume 31

H02-A5

## Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard—Fifth Edition

#### 1 Scope

This document addresses the methodology and devices for the measurement of the erythrocyte sedimentation rate (ESR) phenomenon. It also provides guidance for validation, verification, quality assurance (QA), and quality control (QC) through standardized approaches to ensure good laboratory science and clinical relevance. The intended audience includes manufacturers of such devices, end-user clinical laboratories, accrediting organizations, and regulatory bodies.

End-user clinical laboratories will also find guidance for establishment of working methods for ESR test validation and for QA of their ESR testing method(s).

#### 2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the Centers for Disease Control and Prevention.<sup>20</sup> For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.<sup>21</sup>

#### 3 Terminology

#### 3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents, as well as in World Health Organization (WHO) publications; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI's consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate global application of standards and guidelines.

Specifically, in H02, *accuracy* was changed to *trueness* (where appropriate) for consistency with accepted international usage.

#### 3.2 Definitions

**accuracy (measurement)** – closeness of agreement between a measured quantity value and a true quantity value of a measurand (ISO/IEC Guide 99)<sup>22</sup>; **NOTE 1:** The concept 'measurement accuracy' is not a quantity and is not given a numerical quantity value. A measurement is said to be more accurate when it offers a smaller measurement error (ISO/IEC Guide 99)<sup>22</sup>; **NOTE 2:** The term "measurement accuracy" should not be used for measurement trueness and the term measurement precision should not